Fondaparinux (Arixtra®). HTA ID: 23019

Assessment Status Rapid Review Complete
HTA ID 23019
Drug Fondaparinux
Brand Arixtra®
Indication Fondaparinux (Arixtra®) is indicated for the prevention of Venous Thromboembolic Events, treatment of Acute coronary syndrome, treatment of Superficial vein thrombosis, treatment of Deep vein thrombosis and acute Pulmonary Embolism.
Assessment Process
Rapid review commissioned 19/04/2023
Rapid review resubmission required 04/07/2023
Rapid review completed 28/08/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that fondaparinux not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.